Litcius/Paper detail

Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer's disease-like phenotypes in a preclinical mouse model

Allaura S. Cone, Xuegang Yuan, Li Sun, Leanne C. Duke, Michael Vreones, Allison N. Carrier, Stephanie M. Kenyon, Spencer R. Carver, Sarah Danielle Benthem, Alina C. Stimmell, Shawn C. Moseley, David Hike, Samuel C. Grant, Aaron A. Wilber, James Olcese, David G. Meckes

2021Theranostics213 citationsDOIOpen Access PDF

Abstract

Alzheimer's disease (AD) is an irreversible neurodegenerative disorder that affects more than 44 million people worldwide. Despite the high disease burden, there is no effective treatment for people suffering from AD. Mesenchymal stem cells (MSCs) are multipotent stromal cells that have been widely studied due to their therapeutic potential. However, administration of cells has been found to have a multitude of limitations. Recently, extracellular vesicles (EVs) derived from MSCs have been studied as a therapeutic candidate, as they exhibit similar immunoprotective and immunomodulatory abilities as the host human MSCs.

Topics & Concepts

Mesenchymal stem cellGenetically modified mouseGlial fibrillary acidic proteinStromal cellHippocampusTransgeneStem cellPathologyBiologyMedicineImmunologyCancer researchImmunohistochemistryCell biologyNeuroscienceBiochemistryGeneExtracellular vesicles in diseaseMicroRNA in disease regulationCircular RNAs in diseases
Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer's disease-like phenotypes in a preclinical mouse model | Litcius